Filing Flows › Biofrontera (BFRI) › Q2 2025
Biofrontera (BFRI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Biofrontera (BFRI) reported revenue of $9.0M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +5% from the quarter before. Operating margin was -56.2%, net loss $5.3M (59.0% of revenue).
Biofrontera, Q2 2025: revenue $9.0M (+15% year over year), operating margin -56.2%, net loss $5.3M, operating cash flow −$3.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | +5% | +15% |
| Operating profit | −$5.1M | — | — |
| Net earnings | −$5.3M | — | — |
| Operating cash flow | −$3.0M | — | — |
What changed
Revenue was $9.0M in Q2 2025, up 15% year over year and up 5% from the previous quarter.
Operating costs exceeded revenue by $5.1M, an operating margin of -56.2%. Total costs grew 9% against revenue growth of 15%. The fastest-growing cost line was Research & development (+40%). The quarter ended with a net loss of $5.3M, wider than the previous quarter's $4.2M loss.
Operating cash flow was −$3.0M. Non-cash charges added back $26K of depreciation and amortization and $187K of share-based compensation. Working capital and other items added $2.1M. Capital expenditures of $1K exceeded it, leaving free cash flow of −$3.0M.
Questions
What was Biofrontera's revenue in the second quarter 2025?
Biofrontera (BFRI) reported revenue of $9.0M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +5% from the quarter before.
Was Biofrontera profitable in the second quarter 2025?
Operating loss was $5.1M (-56.2% of revenue) and net loss $5.3M.
Source: Biofrontera 10-Q on SEC EDGAR.